17β-Estradiol-mediated growth inhibition of MDA-MB-468 cells stably transfected with the estrogen receptor: Cell cycle effects

Molecular and Cellular Endocrinology

Volumn 133, Issue 1, 1997, Pages 49-62

  Wang, Weili ^a   Smith III, Roger ^b   Burghardt, Robert ^b   Safe, Stephen H ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Estradiol; Growth inhibition; MDA MB 468 cells

Indexed keywords

AROMATIC HYDROCARBON; CYCLIN DEPENDENT KINASE; CYCLINE; ESTRADIOL; ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; DNA SYNTHESIS; FLOW CYTOMETRY; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; ESTRADIOL; GROWTH INHIBITORS; HUMANS; RECEPTORS, ESTROGEN; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0030663347     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(97)00142-1     Document Type: Article

References (57)

1. Armstrong, D.K., Kaufmann, S.H., Ottaviano, Y.L., Furuya, Y., Buckley, J.A., Isaacs, J.T., Davidson, N.E., 1994. Epidermal growth factor-mediated apoptosis of MDA MB-468 human breast cancer cells. Cancer Res. 54, 5280-5283.
2. Bjorge, J.D., Paterson, A.J., Kudlow, J.E., 1989. Phorbol ester or epidermal growth factor (EGF) stimulates the concurrent accumulation of mRNA for the EGF receptor and its ligand transforming growth factor α in a breast cancer cell line. J. Biol. Chem. 264, 4021-4027.
3. Brunner, N., Osborne, C.K., Spang-Thomsen, M., 1987. Endocrine therapy of human breast cancer grown in nude mice. Breast Cancer Res. Treat. 10, 229-242.
4. Brunner, N., Boulay, V., Fojo, A., Freter, C.E., Lippman, M.E., Clarke, R., 1993a. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res. 53, 283-290.
5. Brunner, N., Frandsen, T.L., Holst-Hansen, C., Bei, M., Thompson, E.W., Wakeling, A.E., Lippman, M.E., Clarke, R., 1993b. MCF7/ LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182780. Cancer Res. 53, 3229-3232.
6. Catherino, W.H., Wolf, D.M., Jordan, V.C., 1995. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Mol. Endocrinol. 9, 1053-1063.
7. Clarke, R., Skaar, T., Baumann, K., Leonessa, F., James, M., Lippman, J., Thompson, E.W., Freter, C., Brunner, N., 1994. Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. Breast Cancer Res. Treat. 31, 237-248.
8. Dickson, R.B., Lippman, M.E., 1995. Growth factors in breast cancer. Endocr. Rev. 16, 559-589.
9. Döhr, O., Vogel, C., Abel, J., 1995. Different response of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-sensitive genes in human breast cancer MCF-7 and MDA-MB-231 cells. Arch. Biochem. Biophys. 321, 405-412.
10. El-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W., Vogelstein, B., 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
11. El-Deiry, W.S., Harper, J.W., O'Connor, P.M., Velculescu, V.E., Canman, C.E., Jackman, J., Pietenpol, J.A., Burrell, M., Hill, D.E., Wang, Y., Wiman, K.G., Vogelstein, B., 1994. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54, 1169-1174.
12. Ennis, B.W., Valverius, E.M., Bates, S.E., Lippman, M.E., Bellot, F., Kris, R., Schlessinger, J., Masui, H., Goldenberg, A., Mendelsohn, J., 1989. Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells. Mol. Endocrinol. 3, 1830-1838.
13. Ethier, S.P., 1995. Growth factor synthesis and human breast cancer progression. J. Natl. Cancer Inst. 87, 964-973.
14. Filmus, J., Pollak, M.N., Cailleau, R., Buick, R.N., 1985. MDA-MB-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem. Biophys. Res. Commun. 128, 898-905.
15. Foster, J.S., Wimalasena, J., 1996. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol. Endocrinol. 10, 488-498.
16. Gaben, A.M., Mester, J., 1991. BALB/C mouse 3T3 fibroblasts expressing human estrogen receptor: effect of estradiol on cell growth. Biochem. Biophys. Res. Commun. 176, 1473-1481.
17. Garcia, M., Derocq, D., Freiss, G., Rochefort, H., 1992. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc. Natl. Acad. Sci. USA 89, 11538-11542.
18. Gorospe, M., Liu, Y., Xu, Q., Chrest, F.J., Holbrook, N.J., 1996. Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2. Mol. Cell. Biol. 16, 762-770.
19. Herman, M.E., Katzenellenbogen, B.S., 1994. Alterations in transforming growth factor-α and -β production and cell responsiveness during the progression of MCF7 human breast cancer cells to estrogen-autonomous growth. Cancer Res. 54, 5867-5874.
20. Horwitz, K.B., Jackson, T.A., Bain, D.L., Richer, J.K., Takimoto, G.S., Tung, L., 1996. Nuclear receptor coactivators corepressors. Mol. Endocrinol. 10, 1167-1177.
21. Irving, J., Feng, J., Wistrom, C., Pikaart, M., Villeponteau, B., 1992. An altered repertoire of fos/jun (AP-1) at the onset of replicative senescence. Exp. Cell Res. 202, 161-166.
22. Jiang, S.Y., Jordan, V.C., 1992. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J. Natl. Cancer Inst. 84, 580-591.
23. Jiang, H., Lin, J., Su, Z.Z., Collart, F.R., Huberman, E., Fisher, P.B., 1994. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 9, 3397-3406.
24. Jordan, V.C., 1993. A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol. 110, 507-517.
25. Katzenellenbogen, B.S., Kendra, K.L., Norman, M.J., Berthois, Y., 1987. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res. 47, 4355-4360.
26. Kelsey, J.L., Berkowitz, G.S., 1988. Breast cancer epidemiology. Cancer Res. 48, 5615-5623.
27. King, R.J., 1992. Progression from steroid sensitive to insensitive state in breast tumours. Cancer Surv. 14, 131-146.
28. Kushner, P.J., Hort, E., Shine, J., Baxter, J.D., Greene, G.L., 1990. Construction of cell lines that express high levels of the human estrogen receptor and are killed by estrogens. Mol. Endocrinol. 4, 1465-1473.
29. Lerner, L.J., Jordan, V.C., 1990. Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res. 50, 4177-4189.
30. Levenson, A.S., Jordan, V.C., 1994. Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines. J. Steroid Biochem. Mol. Biol. 51, 229-239.
31. Lundholt, B.K., Madsen, M.W., Lykkesfeldt, A.E., Petersen, O.W., Briand, P., 1996. Characterization of a nontumorigenic human breast epithelial cell line stably transfected with the human estrogen receptor (ER) cDNA. Mol. Cell. Endocrinol. 119, 47-59.
32. Lykkesfeldt, A.E., Madsen, M.W., Briand, P., 1994. Altered expression of estrogenregulated genes in a tamoxifen-resistant and ICI 164 384 and ICI 182 780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res. 54, 1587-1595.
33. Macleod, K.F., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kinzler, K., Vogelstein, B., Jacks, T., 1995. p53-Dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9, 935-944.
34. Maminta, M.L., Molteni, A., Rosen, S.T., 1991. Stable expression of the human estrogen receptor in HeLa cells by infection: effect of estrogen on cell proliferation and c-myc expression. Mol. Cell. Endocrinol. 78, 61-69.
35. Morrow, M., Jordan, V.C., 1993. Molecular mechanisms of resistance to tamoxifen therapy in breast cancer. Arch. Surg. 128, 1187-1191.
36. Musgrove, E.A., Hamilton, J.A., Lee, C.S., Sweeney, K.J., Watts, C.K., Sutherland, R.L., 1993. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol. Cell. Biol. 13, 3577-3587.
37. Muss, H.B., 1992. Endocrine therapy for advanced breast cancer - a review. Breast Cancer Res. Treat. 21, 15-26.
38. Nigro, J.M., Baker, S.J., Preisinger, A.C., Jessup, J.M., Hostetter, R., Cleary, K., Bigner, S.H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F.S., Weston, A., Modali, R., Harris, C.C., Vogelstein, B., 1989. Mutations in the p53 gene occur in diverse human tumour types. Nature 342, 705-708.
39. Osborne, C.K., Boldt, D.H., Estrada, P., 1984. Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res. 34, 1433-1439.
40. Parker, S.B., Eichele, G., Zhang, P., Rawls, A., Sands, A.T., Bradley, A., Olson, E.N., Harper, J.W., Elledge, S.J., 1995. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 267, 1024-1027.
41. Pink, J.J., Jiang, S.Y., Fritsch, M., Jordan, V.C., 1995. An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. Cancer Res. 55, 2583-2590.
42. Santen, R.J., Manni, A., Harvey, H., Redmond, C., 1990. Endocrine treatment of breast cancer in women. Endocr. Rev. 11, 221-265.
43. WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene 11, 1899-1905.
44. Sutherland, R.L., Reddel, R.R., Green, M.D., 1983. Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. Eur. J. Cancer Clin. Oncol. 19, 307-318.
45. Tate, E.H., Wilder, M.E., Cram, L.S., Wharton, W., 1983. A method for staining 3T3 cell nuclei with propidium iodide in hypotonie solution. Cytometry 4, 211-215.
46. Thomas, T., Thomas, T.J., 1994. Regulation of cyclin B1 by estradiol and polyamines in MCF-7 breast cancer cells. Cancer Res. 54, 1077-1084.
47. Touitou, I., Mathieu, M., Rochefort, H., 1990. Stable transfection of the estrogen receptor cDNA into Hela cells induces estrogen responsiveness of endogenous cathepsin D gene but not of cell growth. Biochem. Biophys. Res. Commun. 169, 109-115.
48. Wang, W., Porter, W., Burghardt, R., Safe, S., 1997. Mechanism of inhibition of MDA-MB-468 breast cancer cell growth by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Carcinogenesis 18, 925-933.
49. Watts, C.K., Parker, M.G., King, R.J., 1989. Stable transfection of the oestrogen receptor gene into a human osteosarcoma cell line. J. Steroid Biochem. 34, 483-490.
50. Watts, C.K., King, R.J., 1994. Overexpression of estrogen receptor in HTB 96 human osteosarcoma cells results in estrogen-induced growth inhibition and receptor cross talk. J. Bone Miner. Res. 9, 1251-1258.
51. Watts, C.K., Brady, A., Sarcevic, B., deFazio, A., Musgrove, E.A., Sutherland, R.L., 1995. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol. Endocrinol. 9, 1804-1813.
52. Webb, P., Lopez, G.N., Greene, G.L., Baxter, J.D., Kushner, P.J., 1992. The limits of the cellular capacity to mediate an estrogen response. Mol. Endocrinol. 6, 157-167.
53. Weisz, A., Bresciani, F., 1993. Estrogen regulation of proto-oncogenes coding for nuclear proteins. Crit. Rev. Oncogen. 4, 361-388.
54. Wilcken, N.R.C., Sarcevic, B., Musgrove, E.A., Sutherland, R.L., 1996. Differential effects of retinoids and antiestrogens on cell cycle progression and cell cycle regulatory genes in human breast cancer cells. Cell Growth Differ. 7, 65-74.
55. Wolf, D.M., Jordan, V.C., 1994. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res. Treat. 31, 129-138.
56. Zajchowski, D.A., Sager, R., 1991. Induction of estrogen-regulated genes differs in immortal and tumorigenic human mammary epithelial cells expressing a recombinant estrogen receptor. Mol. Endocrinol. 5, 1613-1623.
57. Zajchowski, D.A., Sager, R., Webster, L., 1993. Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. Cancer Res. 53, 5004-5011.